
Adriana S Beltran

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10701679/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Abstract P3-15-01: Patients and Researchers Together (PART); a patient-centered tumor tissue collection PARTnership between patients and researchers to increase tissue donations for breast cancer research. Cancer Research, 2022, 82, P3-15-01-P3-15-01.	0.9	0
2	Generation of an induced pluripotent stem cell line (UNCCi002-A) from a healthy donor using a non-integration system to study Cerebral Cavernous Malformation (CCM). Stem Cell Research, 2021, 54, 102421.	0.7	11
3	Pathogenic SPTBN1 variants cause an autosomal dominant neurodevelopmental syndrome. Nature Genetics, 2021, 53, 1006-1021.	21.4	44
4	Generation of an integration-free induced pluripotent stem cell line (UNC001-A) from blood of a healthy individual. Stem Cell Research, 2020, 49, 102015.	0.7	10
5	GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer. Molecular Cancer Research, 2019, 17, 1503-1518.	3.4	39
6	Inheritance of <scp>OCT</scp> 4 predetermines fate choice in human embryonic stem cells. Molecular Systems Biology, 2018, 14, e8140.	7.2	27
7	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex. Cancer Discovery, 2017, 7, 302-321.	9.4	128
8	Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains. Cell Reports, 2015, 11, 390-404.	6.4	254
9	Breaking through an epigenetic wall. Epigenetics, 2013, 8, 164-176.	2.7	20
10	Expression of the Pluripotency Transcription Factor OCT4 in the Normal and Aberrant Mammary Gland. Frontiers in Oncology, 2013, 3, 79.	2.8	28
11	Targeting Serous Epithelial Ovarian Cancer with Designer Zinc Finger Transcription Factors. Journal of Biological Chemistry, 2012, 287, 29873-29886.	3.4	38
12	Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. Nucleic Acids Research, 2012, 40, 6725-6740.	14.5	138
13	Epigenetic reprogramming of cancer cells via targeted DNA methylation. Epigenetics, 2012, 7, 350-360.	2.7	189
14	Generation of tumor-initiating cells by exogenous delivery of OCT4transcription factor. Breast Cancer Research, 2011, 13, R94.	5.0	81
15	Suppression of Breast Tumor Growth and Metastasis by an Engineered Transcription Factor. PLoS ONE, 2011, 6, e24595.	2.5	45
16	Reactivation of <i>MASPIN</i> in non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs). Epigenetics, 2011, 6, 224-235.	2.7	42
17	Remodeling Genomes with Artificial Transcription Factors (ATFs). Methods in Molecular Biology, 2010, 649, 163-182.	0.9	9
18	Rational Design, Selection and Specificity of Artificial Transcription Factors (ATFs): The Influence of Chromatin in Target Gene Regulation. Combinatorial Chemistry and High Throughput Screening, 2008, 11, 146-158.	1.1	17

#	Article	IF	CITATIONS
19	Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor <i>mammary serine protease inhibitor</i> . Molecular Cancer Therapeutics, 2008, 7, 1080-1090.	4.1	58